



**9th Floor
Regent House
Heaton Lane
Stockport
SK4 1BS**

**Tel: 0161 426 9185
Fax: 0161 426 9191**

Email: a.schofield1@nhs.net
Email (PA): gina.wilson1@nhs.net

28th August, 2012

Ref: ASchofield/TicagrelorGP Comms/004/AS/gw

Dear Colleague

Re: - The new GMCCSN/GMMMGM protocol for Antiplatelet usage in Cardiology across Greater Manchester

Over the past couple of years the GMCCSN in partnership with GMMMGM have been looking at the status and affordability of new and existing therapies in cardiology with a major area of work being the new antiplatelet therapies. An output of these discussions has been the development of new antiplatelet guidance for Acute Coronary Syndrome patients following Coronary Artery Stenting.

In June of this year The Commissioning Strategy Board (NHS Manchester Cluster) supported and endorsed the use of Ticagrelor for 12 months for all acute patients (STEMI/NSTEMI/Unstable angina) undergoing coronary intervention which will go live on 4th September 2012.

On discharge, patients will receive a pre-printed antiplatelet medicine information leaflet instructing them on their treatment and medication and a small medication card which they must carry with them at all times.

Following their procedure, patients will continue to be prescribed antiplatelet therapy for 12 months. The Cardiac Formulary Working Group will carry out a full audit of the new protocol with funding secured from the GM Supra District Audit

The new protocols can be found using the following link

http://www.gmccsn.nhs.uk/cmsupload/Ticagrelor_Algorithm_ACS_July_2012_v2.pdf
http://www.gmccsn.nhs.uk/cmsupload/Ticagrelor_Algorithm_PPCI_July_2012_v2.pdf

If you have any further enquiries please contact Amanda Schofield on:
a.schofield1@nhs.net

Yours sincerely

*Document not signed as per NHS Stockport Policy
for transference of documents by email.*

**Dr Farzin Fath-Ordoubadi,
Consultant Cardiologist,
Central Manchester NHS Foundation Trust**

**Andrew White,
Associate Director of Medicines Management,
NHS Greater Manchester**

For and on behalf of the Greater Manchester and Cheshire Cardiac and Stroke Network
and Greater Manchester Medicines Management Group